Floatz Rating
BB70/100
Confidence
Indicative
Sponsor
Jonsson Comprehensive Cancer Center
Modality
Small molecule
Development Phase
Phase 2
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
58High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT01783756CT.gov Phase 1b/2 Trial Using Lapatinib, Everolimus and Capecitabine for Treatment of HER-2 Positive Breast Cancer With CNS Metastasis | — | Completed | — | — | — |
NCT01158274CT.gov RO4929097 and Capecitabine in Treating Patients With Refractory Solid Tumors | — | Completed | — | — | — |
NCT00068588CT.gov GTI-2040 and Capecitabine in Treating Patients With Metastatic Breast Cancer | — | Completed | — | — | — |
NCT00070252CT.gov Neoadjuvant Tipifarnib, Docetaxel, and Capecitabine in Treating Patients With Locally Advanced or Metastatic Solid Tumors or Stage IIIA or Stage IIIB Breast Cancer | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Male Breast Carcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Capecitabine (this asset) | Jonsson Comprehensive Cancer Center | P2 | BB · 70 |
| Cyclophosphamide | Wake Forest University Health Sciences | P2 | BBB |
| Irinotecan | University of California, Irvine | P2 | BBB |
| Nivestim | University of Washington | P2 | BBB |
| Adriamycin | National Cancer Institute (NCI) | P2 | BBB |
| Cediranib | University of Chicago | P2 | BB |
| Tamoxifen | Jose Pablo Leone | P3 | BB |
| Trastuzumab | H. Lee Moffitt Cancer Center and Research Institute | P3 | BB |
| Sargramostim | University of Washington | P2 | BB |
+42 more in the Male Breast Carcinoma cohort
Other indications for Capecitabine
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Rectal Carcinoma | — | P4 | BBB · 73 |
| Hormone Receptor-Positive Breast Cancer | — | P4 | BBB · 72 |
| Colorectal Neoplasm | — | P4 | BB · 71 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Capecitabine in Male Breast Carcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/capecitabine-male-breast-carcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →